How is tirzepatide different from Ozempic?
Tirzepatide is researched as a dual GIP/GLP‑1 receptor agonist. Ozempic (semaglutide) is a GLP‑1 receptor agonist. That means tirzepatide targets two incretin pathways, while semaglutide targets one.
For GLP‑1 design context, see GLP‑1 agonist generations.
Disclaimer: The statements are for informational purposes only and not intended to treat, diagnose, or cure any disease and all products mentioned are for research purposes only and not for human use.





